首页> 外文OA文献 >Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

【2h】

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

机译：校正：在复发或难治性B细胞NHL和CLL中，第一阶段1研究BTK抑制剂GDC-0853

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
John C. Byrd; Stephen Smith; Nina Wagner-Johnston; Jeff Sharman; Andy I. Chen; Ranjana Advani; Bradley Augustson; Paula Marlton; S. Renee Commerford; Kwame Okrah; Lichuan Liu; Elaine Murray; Elicia Penuel; Ashley F. Ward; Ian W. Flinn;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation [J] . Park Jae H., Palomba Maria Lia, Batlevi Connie Lee, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：在复发或难发的NHL和CLL中的CD19-靶向19-28Z / 4-1BBL“装甲”CAR T细胞的一期第一阶段临床试验，包括Rictter的转化
2. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study [J] . Italiano Antoine, Soria Jean-Charles, Toulmonde Maud, The lancet oncology . 2018 ,第5期

机译：Tazemetostat，一种EzH2抑制剂，复发或难治性B细胞非霍奇金淋巴瘤和先进的实体瘤：一载最初的，开放标签，第1期研究
3. Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies [J] . Qi Junyuan, Song Yuqin, Jiang Bo, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：来自一期，YY-20394的第一阶段研究，一部分，高效的B-Cell Matignacies的患者，YY-20394的第一阶段，高效性和高效的PI3K Delta抑制剂的初步结果
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL [O] . John C. Byrd, Stephen Smith, Nina Wagner-Johnston, 2019

机译：更正：BTK抑制剂GDC-0853在复发或难治性B细胞NHL和CLL中的首次人类1期研究
7. A phase I clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. [O] . Walter, Harriet S., Rule, Simon A., Dyer, Martin J.S., 2015

机译：选择性BTK抑制剂ONO / GS-4059在复发和难治性成熟B细胞恶性肿瘤中的I期临床试验。

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

著录项

相似文献

相关主题

期刊订阅